u/yannick_petrov

Small correction — the shop in that story has no independent testing on file at all, which is different from having a bad record.

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

salt forms are the recurring argument and the answer is boring

shortage status changes and the whole arrangement changes with it

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Agreed — and the endpoint definitions are where the actual claim lives.

Adding the standing caveat — unapproved compound, research material is not for human use.

Sorted by controversial for a week and found four of the best threads I have read here.

Is that a weight number from a different programme?

Small fix — dual agonist, GLP-1 and glucagon.

Agreed — and the endpoint definitions are where the actual claim lives.

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

ask which facility, then ask for their testing

sponsor disclosure is on the about page in full

Agreed — concrete wording or it is not a proposal.

the titration in the trials was slow and deliberate

the thing that went wrong is usually procedural, not dramatic

Told everybody, then stopped, then had to tell everybody that too. That was harder than any of the rest of it.

This. Modmail first is not bureaucracy; it stops individual cases turning into a public pile-on.

Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

Total transit decomposes into first mile, international leg, clearance and last mile. Only the first two are meaningfully under the shipper’s control and most reported variance sits in the last two.

regional stock changes everything about transit

Same.

gradient_goblin is right about regional stock. It changes the shape of the distribution, not just the mean.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

Disagree. That is a customs hold, not a carrier delay, and lumping them together makes the lane table wrong.

Stopped for financial reasons and regained most of it. Not a moral story, just a budget and a documented outcome.

do not import intuitions from the obesity programmes

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Four observations is not a distribution. The lane tables here only became predictive once individual routes had a dozen or more reports behind them.

How many shipments does your figure cover?

Which receptor family are you attributing that effect to?

The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.

research material is not approved for human use, which is why the clinical record here is thin

the ranking formula is published, go and read it

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

That is a packaging observation, not a transit observation. Worth posting, worth separating.

Four observations is not a distribution. The lane tables here only became predictive once individual routes had a dozen or more reports behind them.

Left up and flaired Proposal — it has replacement wording, which is what this board asks for.

Adding the practical note — the formula is published and you can reproduce the ordering yourself.